| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1999;67:1370-1375
© 1999 The Society of Thoracic Surgeons
a Thoraxcenter, University Hospital of Groningen, Groningen, the Netherlands
Accepted for publication December 3, 1998.
Address reprint requests to Dr Mariani, Thoraxcenter, University Hospital Groningen, Hanzeplein, 1, PO Box 30.001, 9700 RB Groningen, the Netherlands
e-mail: M.Mariani{at}thorax.azg.nl
 |
Abstract |
|---|
 Top Abstract IntroductionPatients and methodsResultsCommentAcknowledgmentsReferences |
|---|
Methods. We prospectively studied coagulation in 22 patients who underwent off-pump coronary operation either through a midline sternotomy (n = 14) or with minimally invasive anterolateral thoracotomy (n = 8).
Results. Procoagulant activity, represented by prothrombin factor 1 and 2, remained at baseline levels during operation but increased significantly on postoperative day 1. Factor VII remained at baseline levels during the operation but decreased significantly on postoperative day 1. Fibrinolysis was increased as indicated by the fibrin degradation products on postoperative day 1. A promoted hemostasis attributable to endothelial activation was indicated by the increase in von Willebrand factor on postoperative day 1. Platelets counts and platelet activation (ß-thromboglobulin) remained at baseline levels after the operation. No adverse clinical events occurred.
Conclusions. Patients undergoing off-pump coronary operation show an increased procoagulant activity in the first postoperative 24 hours regardless of the surgical approach (midline sternotomy or anterolateral thoracotomy). This procoagulant activity is not mediated by platelet-related factors. Therefore, a specific perioperative prophylactic pharmacologic regimen is advisable.
|
Introduction |
|---|
|
TopAbstractIntroductionPatients and methodsResultsCommentAcknowledgmentsReferences |
|---|
However, the preserved hemostasis may result in a procoagulant activity after off-pump coronary operation. This procoagulant activity is a well-known phenomenon in major general surgery and it is also a phenomenon to be expected after major surgical procedures such as coronary operation. The procoagulant activity increases the risk of venous thrombosis and potentially endangers the patency of coronary anastomoses. In addition, operating on the beating heart and the use of minimal surgical access may increase the technical difficulty of coronary operation and some investigators have expressed concern for an excessive rate of graft failure [13–17]. Some of these failures and complications could be explained by the occurrence of graft thrombosis.
To investigate the procoagulant activity after off-pump coronary operation we prospectively studied 22 patients with single-vessel disease involving the left anterior descending artery (LAD) who underwent off-pump coronary operation. Because the extent of tissue damage may influence the procoagulant activity, the patients were randomly assigned to OPCAB or MICS. The main coagulation and clinical variables were measured intraoperatively and postoperatively.
|
Patients and methods |
|---|
|
TopAbstractIntroductionPatients and methodsResultsCommentAcknowledgmentsReferences |
|---|
Patients
From May to October 1997, 22 consecutive patients with single-vessel disease entered the study and were randomly assigned to two treatments: 14 underwent OPCAB through a midline sternotomy and 8 underwent MICS with a small anterolateral thoracotomy. Mean age was 61.5 ± 11 years (range, 37 to 83 years). There were no differences in age and preoperative risk factors between the two groups. Inclusion criteria were the presence of single-vessel disease involving the LAD (type B2 or C stenosis [18]) with documented myocardial ischemia and a normal or moderately depressed ventricular function (ejection fraction, > 35%). All patients underwent elective and first operations. Exclusion criteria were the presence of any associated cardiac disease requiring surgical treatment with the use of cardiopulmonary bypass (eg, left ventricular aneurysm or valvular disease), myocardial infarction either evolving or acute (within 48 hours) or recent (within 2 weeks). The use of intravenous heparin before operation was also considered as an exclusion criterion.
A panel of cardiologists and cardiac surgeons gave general consensus on the feasibility of both OPCAB and MICS. Then OPCAB and MICS were presented to the patients who were informed of MICS as an alternative treatment to OPCAB, which was presented as the standard treatment. The final choice of treatment was left to the patient, who gave informed consent.
Surgical techniques
Off-pump coronary artery bypass
Patients were prepared and draped as for a conventional coronary operation down to the transverse umbilical line. Down from this line the patients were covered with a warm air-cushion rewarming blanket to avoid heat dispersion and the consequent hypothermia during the procedure. The skin incision was begun 2 to 3 cm caudal to the sternal notch and was extended to a point 2 to 3 cm cranially to the xiphoid. A full midline sternotomy was performed. The left internal mammary artery was harvested as a pedicle with electrocautery from its origin to its distal bifurcation. Then heparin was given (100 IU/kg) and the mammary pedicle was divided. The ACT was checked 3 minutes later. A sternal spreader carrying a coronary stabilizer (MV Access Platform, CardioThoracic System, Inc, Portola Valley, CA) was positioned in the sternal wound. The pericardial sac was opened with a conventional reversed T incision and suspended with stay sutures. The coronary stabilizer was positioned and locked in place. The LAD was surrounded by two looping 5-0 polypropylene sutures, proximally and distally to the chosen site for the anastomosis. The LAD was opened and the mammary-to-coronary anastomosis was performed with a running 7-0 or 8-0 polypropylene suture. No protamine was given at the end of the procedure. The pericardium was closed after the procedure, the midline sternotomy was closed in layers, and three drains (one left pleural, one pericardial, one mediastinal) were left in place.
Minimally invasive coronary thoracotomy
Patients were prepared as previously described [4]. A double-lumen endotracheal tube was used. A skin incision of approximately 8 to 10 cm was made in the fifth intercostal space. Once the pleural cavity had been opened, the left lung was deflated and the left internal mammary artery was identified by palpation.
The wound spreader (IMA Retractor, CardioThoracic System) was secured in place and gently opened to avoid rib fractures. The left internal mammary artery was harvested as a pedicle from the first rib down to the seventh intercostal space. Then heparin was given (100 IU/kg) and the mammary pedicle was divided. The ACT was checked 3 minutes later. The LAD was surrounded by two looping 5-0 polypropylene sutures, proximally and distally to the chosen site for the anastomosis. The coronary stabilizer (Stabilizer, CardioThoracic System) was positioned and locked into place. The LAD was opened and the mammary-to-coronary anastomosis was performed with a running 7-0 or 8-0 polypropylene suture. No protamine was given at the end of the procedure. The small thoracotomy wound was closed in layers and one pleural drain was left in place.
In both groups the patients were transferred to the intensive care unit still intubated. Extubation was scheduled in the intensive care unit after stabilization of hemodynamic and respiratory states.
All patients received 80 mg of oral aspirin and 7,500 IU Fraxiparine subcutaneously beginning on the afternoon of postoperative day 1. Subcutaneous Fraxiparine was continued until discharge and then suspended. Oral aspirin was continued after discharge. No additional anticoagulation drug was administered either preoperatively or on the day of the operation.
Laboratory tests
Blood samples were taken before surgical incision (baseline), 3 minutes after heparinization (T1), at the end of operation (T2), and 24 hours after operation (T3) from the indwelling radial artery catheter. Platelet count and hematocrit were measured from blood samples anticoagulated with 0.1 mmol/L ethylenediaminetetraacetic acid and counted by a cell counter (Cell–Dyn 610, Sequoia-Turner Corp, CA). Blood samples anticoagulated with 3.06% sodium citrate and hirudin were centrifuged at 1,000 g for 10 minutes. After centrifugation, the platelet-poor plasma was divided in separate aliquots and stored at -80°C for further determination of coagulation and fibrinolysis. Prothrombin F1+2 was determined by an enzyme-linked immunosorbent assay (Behringwerke AG, Marburg, Germany; normal values, 0.4 to 1.1 nmol/L). Factor VII was determined by a chromogenic assay (Chromogenix AB, Molndal, Sweden). Fibrin degradation was determined by an enzyme-linked immunosorbent assay (Organon Teknika, Boxtel, the Netherlands; normal upper limit, 650 ng/mL).
Activation of platelets was indicated by the release of ß-thromboglobulin as determined by a radioimmunoassay (Amersham International, Inc, Amersham, UK). The von Willebrand factor was determined by an enzyme-linked immunosorbent assay (Gradipore Ltd, North Ryde, Australia).
Statistical analysis
All clinical and laboratory data were collected prospectively in a customized database. All data were processed using the SPSS 7.5 statistical package (SPSS, Inc, Chicago, IL). All continuous variables are expressed as mean ± standard deviation. All tests of significance were two-tailed: 
2 and Fisher’s exact test were used for discrete variables and analysis of variance and Mann-Whitney for continuous variables. The Student’s t test was used to compare the values of the variables between the two treatments and within each treatment at different times. We considered a statistical probability of less than 0.05 as indicative of significance.
|
Results |
|---|
|
TopAbstractIntroductionPatients and methodsResultsCommentAcknowledgmentsReferences |
|---|
Laboratory results
Procoagulant activity, represented by prothrombin F1+2, was low and stable during operation (Table 1). There was no significant difference between the OPCAB and the MICS groups. However, prothrombin F1+2 increased significantly in both groups on postoperative day 1 compared with baseline as well as with the concentration at the end of the operation (T2; Fig 1). Factor VII was stable during the operation but decreased significantly on postoperative day 1 in both groups (Fig 2), indicating the consumption of coagulation factors through the extrinsic pathway. Fibrinolysis was also activated in both groups as indicated by the significant increase in fibrin degradation products on postoperative day 1 (Fig 3). A promoted hemostasis as a result of endothelial activation was also present on postoperative day 1 as indicated by the significant increase in von Willebrand factor (Table 2).
|
|
|
|
|
|
|
Comment |
|---|
|
TopAbstractIntroductionPatients and methodsResultsCommentAcknowledgmentsReferences |
|---|
Although we have not encountered clinical evidence of this problem in this series (all 22 patients were free from myocardial ischemia or pulmonary embolism postoperatively), the previous clinical experience and the result of this study may indicate a possible danger for the early graft patency as well as an increased risk of venous thrombosis.
In fact, the results of this study clearly show that patients undergoing both OPCAB and MICS have a procoagulant activity that is strongly evident 24 hours after operation. This is indicated by the increase in F1+2 and fibrin degradation products and by the decrease in Factor VII (Figs 1 to 3 and Table 1). The significant increase in von Willebrand factor on postoperative day 1 (Table 2) is further supporting this evidence. In fact, the increase in von Willebrand factor is an indirect sign of promoted hemostasis as a result of endothelial activation. Moreover, the procoagulant activity observed in this study is not influenced by the contribution of platelet-related factors. In fact, the total number of platelets remains unchanged and no platelet degranulation is detectable.
Current protocols of perioperative anticoagulation are substantially empirical [1–5] and derived from the protocols applied to patients who undergo conventional coronary operations with cardiopulmonary bypass. However, cardiopulmonary bypass is known to affect hemostasis and platelet function for at least 24 hours. Conversely, patients undergoing off-pump coronary operation are lacking the impairing effect of cardiopulmonary bypass on hemostasis.
In addition, Oltrona and colleagues [23] have reported that heparin administration cannot suppress thrombin activity in an undetected percentage of patients showing a heparin-resistant thrombin activity. Heparin-resistant thrombin activity is associated with the evidence of intravascular thrombosis, which can play a role in early occlusive complications as well as in promoting late restenosis [23, 24]. This intravascular thrombosis is most likely to occur when the ACT does not increase to more than 300 seconds after the administration of heparin [23]. In our series the average ACT was less than 300 seconds after the administration of 100 IU/kg heparin. Therefore, this dose of heparin, conventionally (and empirically) accepted for off-pump coronary operation, is not enough to track and subsequently to treat patients with heparin-resistant thrombin activity.
In conclusion, patients undergoing off-pump coronary operation face an increased procoagulant activity regardless of what surgical access is used (midline sternotomy or anterolateral thoracotomy). This increased procoagulant activity is independent of platelet activation. As a result of this increased procoagulant activity patients undergoing off-pump coronary operation should be considered at increased risk of thrombotic graft occlusion and pulmonary embolism in the first postoperative 24 hours. Therefore, we believe that the perioperative anticoagulation policy for patients undergoing off-pump coronary operation should be more aggressive than that for patients undergoing conventional coronary procedures with cardiopulmonary bypass. Therefore, a careful anticoagulation prophylactic regimen should be begun the day before operation and should be continued immediately after the operation up to the first postoperative 24 hours. In addition the dose of heparin administered intraoperatively should be enough to keep the ACT more than 300 seconds. We do not advise to antagonize the heparin with protamine at the end of the procedure, unless an uncontrollable diffuse bleeding should be present.
Prospective randomized trials comparing conventional postoperative treatment for coronary patients and a combined preoperative and postoperative treatment are advisable to clarify further this issue.
|
Acknowledgments |
|---|
|
TopAbstractIntroductionPatients and methodsResultsCommentAcknowledgmentsReferences |
|---|
|
References |
|---|
|
TopAbstractIntroductionPatients and methodsResultsCommentAcknowledgmentsReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  W. B. Halbersma, S. C. Arrigoni, G. Mecozzi, J. G. Grandjean, A. P. Kappetein, J. van der Palen, F. Zijlstra, and M. A. Mariani Four-year outcome of OPCAB no-touch with total arterial Y-graft: making the best treatment a daily practice. Ann. Thorac. Surg., September 1, 2009; 88(3): 796 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shimokawa, S. Manabe, T. Sawada, S. Matsuyama, T. Fukui, and S. Takanashi Intermediate-term patency of saphenous vein graft with a clampless hand-sewn proximal anastomosis device after off-pump coronary bypass grafting. Ann. Thorac. Surg., May 1, 2009; 87(5): 1416 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ranucci, A. Balduini, A. Ditta, A. Boncilli, and S. Brozzi A Systematic Review of Biocompatible Cardiopulmonary Bypass Circuits and Clinical Outcome Ann. Thorac. Surg., April 1, 2009; 87(4): 1311 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Jervis, V. Senthilnathan, and A. B. Lerner Management of a Patient with Lupus Anticoagulant and Antiphospholipid Syndrome for Off-Pump Coronary Artery Bypass Grafting Using the Hepcon(R) System Anesth. Analg., April 1, 2009; 108(4): 1116 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bednar, P. Osmancik, T. Vanek, H. Mocikova, M. Jares, Z. Straka, and P. Widimsky Platelet activity and aspirin efficacy after off-pump compared with on-pump coronary artery bypass surgery: results from the prospective randomized trial PRAGUE 11-Coronary Artery Bypass and REactivity of Thrombocytes (CABARET). J. Thorac. Cardiovasc. Surg., October 1, 2008; 136(4): 1054 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Briffa Off pump coronary artery bypass: a passing fad or ready for prime time? Eur. Heart J., June 1, 2008; 29(11): 1346 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Untch, W. P. Jeske, J. Schwartz, S. Botkin, M. Prechel, J. M. Walenga, and M. Bakhos Inflammatory and Hemostatic Activation in Patients Undergoing Off-Pump Coronary Artery Bypass Grafting Clinical and Applied Thrombosis/Hemostasis, April 1, 2008; 14(2): 141 - 148. [Abstract] [PDF]
|
|
|
|
|
|
K.-B. Kim, K. R. Cho, and D. S. Jeong Midterm angiographic follow-up after off-pump coronary artery bypass: serial comparison using early, 1-year, and 5-year postoperative angiograms. J. Thorac. Cardiovasc. Surg., February 1, 2008; 135(2): 300 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Cho, D. S. Jeong, and K.-B. Kim Influence of vein graft use on postoperative 1-year results after off-pump coronary artery bypass surgery Eur. J. Cardiothorac. Surg., November 1, 2007; 32(5): 718 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Shim, Y. S. Choi, Y. J. Oh, S. O. Bang, K. J. Yoo, and Y. L. Kwak Effects of preoperative aspirin and clopidogrel therapy on perioperative blood loss and blood transfusion requirements in patients undergoing off-pump coronary artery bypass graft surgery J. Thorac. Cardiovasc. Surg., July 1, 2007; 134(1): 59 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ballotta, H. Z. Saleh, H. W. El Baghdady, M. Gomaa, F. Belloli, H. Kandil, Y. Balbaa, F. Bettini, E. Bossone, L. Menicanti, et al. Comparison of early platelet activation in patients undergoing on-pump versus off-pump coronary artery bypass surgery J. Thorac. Cardiovasc. Surg., July 1, 2007; 134(1): 132 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. N. Hoel, V. Videm, T. E. Mollnes, K. Saatvedt, F. Brosstad, A. E. Fiane, E. Fosse, and J. L. Svennevig Off-pump cardiac surgery abolishes complement activation Perfusion, July 1, 2007; 22(4): 251 - 256. [Abstract] [PDF]
|
|
|
|
 |
|
 A. T Gurbuz, O. Findik, H. Cui, and A. Aytac Radial Artery Graft Use and Off-Pump Coronary Artery Bypass Surgery Outcome Asian Cardiovasc Thorac Ann, April 1, 2007; 15(2): 106 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Novitzky, A L. Shroyer, J. F Collins, G. O McDonald, J. Lucke, B. Hattler, E. Kozora, D. D Bradham, J. Baltz, F. L Grover, et al. A study design to assess the safety and efficacy of on-pump versus off-pump coronary bypass grafting: the ROOBY trial Clinical Trials, February 1, 2007; 4(1): 81 - 91. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Ben Ari, E. Elinav, A. Elami, and I. Matot Off-pump coronary artery bypass grafting in a patient with Child class C liver cirrhosis awaiting liver transplantation Br. J. Anaesth., October 1, 2006; 97(4): 468 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Al-Ruzzeh, S. George, M. Bustami, J. Wray, C. Ilsley, T. Athanasiou, and M. Amrani Effect of off-pump coronary artery bypass surgery on clinical, angiographic, neurocognitive, and quality of life outcomes: randomised controlled trial BMJ, June 10, 2006; 332(7554): 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Halkos, W. A. Cooper, R. Petersen, J. D. Puskas, O. M. Lattouf, J. M. Craver, and R. A. Guyton Early Administration of Clopidogrel Is Safe After Off-Pump Coronary Artery Bypass Surgery Ann. Thorac. Surg., March 1, 2006; 81(3): 815 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Gurbuz, A. A. Zia, A. C. Vuran, H. Cui, and A. Aytac Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study Eur. J. Cardiothorac. Surg., February 1, 2006; 29(2): 190 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Paparella, A. Galeone, M. T. Venneri, M. Coviello, G. Scrascia, N. Marraudino, M. Quaranta, L. de Luca Tupputi Schinosa, and S. J. Brister Activation of the coagulation system during coronary artery bypass grafting: Comparison between on-pump and off-pump techniques J. Thorac. Cardiovasc. Surg., February 1, 2006; 131(2): 290 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Poston, C. White, J. Gu, J. Brown, J. Gammie, R. N. Pierson, A. Lee, I. Connerney, T. Avari, R. Christenson, et al. Aprotinin Shows Both Hemostatic and Antithrombotic Effects During Off-Pump Coronary Artery Bypass Grafting Ann. Thorac. Surg., January 1, 2006; 81(1): 104 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Vanek, M. Jares, R. Fajt, Z. Straka, K. Jirasek, M. Kolesar, P. Brucek, and M. Maly Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo) Eur. J. Cardiothorac. Surg., October 1, 2005; 28(4): 563 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Vedin, A. Antovic, A. Ericsson, and J. Vaage Hemostasis in Off-Pump Compared to On-Pump Coronary Artery Bypass Grafting: A Prospective, Randomized Study Ann. Thorac. Surg., August 1, 2005; 80(2): 586 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Dixon, J. Santamaria, and D. Campbell Coagulation Activation and Organ Dysfunction Following Cardiac Surgery Chest, July 1, 2005; 128(1): 229 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Poston, J. Gu, J. Manchio, A. Lee, J. Brown, J. Gammie, C. White, and B. P. Griffith Platelet function tests predict bleeding and thrombotic events after off-pump coronary bypass grafting Eur. J. Cardiothorac. Surg., April 1, 2005; 27(4): 584 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Zimmermann, M. Kurt, A. Wenk, J. Winter, E. Gams, and T. Hohlfeld Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting? Eur. J. Cardiothorac. Surg., April 1, 2005; 27(4): 606 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Pepper Controversies in Off-pump Coronary Artery Surgery Clin. Med. Res., February 1, 2005; 3(1): 27 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G Raja, Z. Haider, and H. Zaman Off-Pump Coronary Artery Bypass Surgery: Analysis of 5-Year Experience Asian Cardiovasc Thorac Ann, December 1, 2004; 12(4): 306 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Boonstra and W. van Oeveren Clopidogrel and Postoperative Bleeding Ann. Thorac. Surg., November 1, 2004; 78(5): 1522 - 1522. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Mariani, A. D'Alfonso, and J. G. Grandjean Total Arterial Off-Pump Coronary Surgery: Time to Change Our Habits? Ann. Thorac. Surg., November 1, 2004; 78(5): 1591 - 1597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lo, R. Fijnheer, D. Castigliego, C. Borst, C. J. Kalkman, and A. P. Nierich Activation of Hemostasis After Coronary Artery Bypass Grafting With or Without Cardiopulmonary Bypass Anesth. Analg., September 1, 2004; 99(3): 634 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Englberger, F. F. Immer, F. S. Eckstein, P. A. Berdat, A. Haeberli, and T. P. Carrel Off-Pump coronary artery bypass operation does not increase procoagulant and fibrinolytic activity: preliminary results Ann. Thorac. Surg., May 1, 2004; 77(5): 1560 - 1566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Casati, S. Benussi, L. Sandrelli, M. A. Grasso, S. Spagnolo, and A. D'Angelo Intraoperative Moderate Acute Normovolemic Hemodilution Associated with a Comprehensive Blood-Sparing Protocol in Off-Pump Coronary Surgery Anesth. Analg., May 1, 2004; 98(5): 1217 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Puskas, W. H. Williams, E. M. Mahoney, P. R. Huber, P. C. Block, P. G. Duke, J. R. Staples, K. E. Glas, J. J. Marshall, M. E. Leimbach, et al. Off-Pump vs Conventional Coronary Artery Bypass Grafting: Early and 1-Year Graft Patency, Cost, and Quality-of-Life Outcomes: A Randomized Trial JAMA, April 21, 2004; 291(15): 1841 - 1849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Hangler, K. Pfaller, E. Ruttmann, D. Hoefer, T. Schachner, G. Laufer, and H. Antretter Effects of intracoronary shunts on coronary endothelial coating in the human beating heart Ann. Thorac. Surg., March 1, 2004; 77(3): 776 - 780. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F. Merry, P. J. Raudkivi, N. G. Middleton, J. M. McDougall, P. Nand, B. P. Mills, B. J. Webber, C. M. Frampton, and H. D. White Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery Ann. Thorac. Surg., March 1, 2004; 77(3): 925 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-G. Chassot, P. van der Linden, M. Zaugg, X. M. Mueller, and D. R. Spahn Off-pump coronary artery bypass surgery: physiology and anaesthetic management{dagger} Br. J. Anaesth., March 1, 2004; 92(3): 400 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Biglioli, A. Cannata, F. Alamanni, M. Naliato, M. Porqueddu, M. Zanobini, E. Tremoli, and A. Parolari Biological effects of off-pump vs. on-pump coronary artery surgery: focus on inflammation, hemostasis and oxidative stress Eur. J. Cardiothorac. Surg., August 1, 2003; 24(2): 260 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Kurlansky Is there a hypercoagulable state after off-pump coronary artery bypass surgery? What do we know and what can we do? J. Thorac. Cardiovasc. Surg., July 1, 2003; 126(1): 7 - 10. [Full Text] [PDF]
|
|
|
|
|
|
H. Y. Karagoz, M. Kurtoglu, B. Bakkaloglu, B. Sonmez, T. Cetintas, and K. Bayazit Coronary artery bypass grafting in the awake patient: Three years' experience in 137 patients J. Thorac. Cardiovasc. Surg., June 1, 2003; 125(6): 1401 - 1404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Levy and K. A. Tanaka Inflammatory response to cardiopulmonary bypass Ann. Thorac. Surg., February 1, 2003; 75(2): S715 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Dewey and M. J. Mack Myocardial Revascularization Without Cardiopulmonary Bypass Card. Surg. Adult, January 1, 2003; 2(2003): 609 - 625. [Full Text]
|
|
|
|
|
|
C. Baufreton, J. L. de Brux, P. Binuani, J.-J. Corbeau, J. B. Subayi, J. C. Daniel, and P. Treanor A combined approach for improving cardiopulmonary bypass in coronary artery surgery: a pilot study Perfusion, December 1, 2002; 17(6): 407 - 413. [Abstract] [PDF]
|
|
|
|
|
|
L. Englberger, P. Markart, F.S. Eckstein, F.F. Immer, P.A. Berdat, and T.P. Carrel Aprotinin reduces blood loss in off-pump coronary artery bypass (OPCAB) surgery Eur. J. Cardiothorac. Surg., October 1, 2002; 22(4): 545 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-B. Kim, K. R. Cho, W.-I. Chang, C. Lim, B. M. Ham, and Y. L. Kim Bilateral skeletonized internal thoracic artery graftings in off-pump coronary artery bypass: early result of Y versus in situ grafts Ann. Thorac. Surg., October 1, 2002; 74(4): S1371 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R L Quigley, D W Fried, R Salenger, J Pym, and R Y Highbloom Thrombelastographic changes in OPCAB surgical patients Perfusion, September 1, 2002; 17(5): 363 - 367. [Abstract] [PDF]
|
|
|
|
|
|
R. G. Demaria, S. Fortier, and L. P. Perrault Coronary endothelial damage during off-pump CABG related to coronary-clamping and gas insufflation Eur. J. Cardiothorac. Surg., December 1, 2001; 20(6): 1270 - 1271. [Full Text] [PDF]
|
|
|
|
|
|
Y. Okazaki, K. Takarabe, and T. Itoh Reply to Demaria et al. Eur. J. Cardiothorac. Surg., December 1, 2001; 20(6): 1272 - 1272. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Capdeville and J. H. Lee Off-Pump Coronary Artery Bypass Surgery: Revival of an Old Technique Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 2001; 5(4): 345 - 361. [Abstract] [PDF]
|
|
|
|
|
|
K.-B. Kim, C. Lim, C. Lee, I.-H. Chae, B.-H. Oh, M.-M. Lee, and Y.-B. Park Off-pump coronary artery bypass may decrease the patency of saphenous vein grafts Ann. Thorac. Surg., September 1, 2001; 72(3): S1033 - 1037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Casati, C. Gerli, A. Franco, G. Torri, A. D'Angelo, S. Benussi, and O. Alfieri Tranexamic acid in off-pump coronary surgery: a preliminary, randomized, double-blind, placebo-controlled study Ann. Thorac. Surg., August 1, 2001; 72(2): 470 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Hangler, K. Pfaller, H. Antretter, O. E. Dapunt, and J. O. Bonatti Coronary endothelial injury after local occlusion on the human beating heart Ann. Thorac. Surg., January 1, 2001; 71(1): 122 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Y. Karagoz, B. Sonmez, B. Bakkaloglu, M. Kurtoglu, M. Erdinc, A. Turkeli, and K. Bayazit Coronary artery bypass grafting in the conscious patient without endotracheal general anesthesia Ann. Thorac. Surg., July 1, 2000; 70(1): 91 - 96. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
